How Eric Lefkofsky is Revolutionizing Cancer Treatment with Tempus

According to studies, almost 40% of the adults living in the US will be diagnosed with cancer at a certain point in their lives. Statistics revealed by the National Cancer Institute show that nearly 14.5 million citizens in the US were suffering from cancer in 2014. As of 2024, this figure is expected to go even up to over 19 million. However, there is good news that the prognosis is changing to the better with outstanding advances that are being made by firms like Tempus. A pioneer in the precision medicine that data enabled, Tempus was co-founded by Eric Lefkofsky who is also the co-founder of Groupon.

The introduction of EHRs, Electronic Health Records, indicated that the industry of healthcare keeping up with the latest technology. Eric Lefkofsky got to learn cancer after his wife was found to have breast cancer. After doing some in-depth research, he discovered that there were gaping holes in the healthcare field when it comes to digital technology and data collection. It is for this very reason that Eric decided to start Tempus in order to revolutionize the manner in which important information about cancer patients is collected and stored. Tempus came up with software that has capabilities in optical character recognition and natural language processing.

Through the leadership of Eric Lefkofsky, Tempus enables clinical information regarding a cancer patient to be put together with molecular information collected via genome sequencing. Tempus helps to come up with a technology healthcare solution that will enable doctors to successfully pair patients suffering from cancer with effective treatments.

Born in Southfield, Michigan in 1969, Eric Lefkofsky is the co-founder of Tempus. He attended the University of Michigan, Ann Arbor where he graduated in 1991 with high honors. He also went to the University of Michigan law School where he acquired a Juris Doctor Degree. Although Eric did not venture into law as per his educational background, he managed to become a successful entrepreneur and became known internationally.

Apart from working at Tempus, he is a member of the Director’s Board at Lurie’s Children’s Memorial Hospital, Chicago as well as the Art Institute of Chicago. Eric Lefkofsky is now an adjunct professor serving at the University of Chicago’s Booth School of Business.

To know more visit @:

Clay B. Siegall’s knowledge of ADCs and Cancer Treatment

Clay B. Siegall is a science expert who is renowned due to the excellent research that he has conducted on cancer. He is a co-founder of a pharmaceutical corporation that is known as Seattle Genetics. Siegall also serves the company as its CEO and president. Since the founding of the enterprise in 1998, it has been dedicated to conducting detailed research, scientific discoveries, and creating new drugs. Clay has been working hard to develop various therapies that be utilized in treating cancer patients. The doctor has played a significant role in the developing antibody-drug conjugates (ADCs) at Seattle Genetics. The first ADC that the company created was called ADCETRIS®. The drug was licensed by the FDA in 2011, and it is currently sold in more than 65 countries. Seattle Genetic collaborated with Takeda Pharmaceutical Company to ensure that ADCETRIS® becomes an international brand. The company’s researchers have been striving to develop different types of ADC that can cure cancer.


Dr. Clay Seigall has assisted his company is getting different strategic licenses that have enabled it to manufacture and supply its drugs on a global scale. The primary medicines that have been developed by the firm include GlaxoSmithKline, AbbVie, Genentech, and Pfizer. The corporation has currently raised revenue of more than $350 million from selling the drugs across the world. Seattle Genetic’s technology has been used in the formation of more than 20 ADCs. The company manufactures the drugs internally and also joins efforts with other corporations to develop them externally. Clay Siegall has established excellent strategies that have assisted the firm in securing funding. It has raised more than $1.2 billion since 2001.


Clay had an opportunity to work for different pharmaceutical firms before he established Seattle Genetics. His first employer was the National Cancer Institute, and he later moved to Bristol-Myers Squibb Pharmaceutical Research Institute. He has also sat on the management boards of corporations such as Washington Roundtable, BioPharmaceutica, and Ultragenyx Pharmaceutical. Siegall is focused on the research that he conducts. He has to date written more than 70 publications and has 15 patents for the products that he has developed.


Cancer Treatment Centers of America Lends A Helping Hand

Cancer Treatment Centers of America is collaborating with Allscripts and NantHealth. The collaboration is applying a custom practical solution that allows NantHealth quantifiable solutions to happen. With smooth assimilation of solutions Clinical Pathways will be able to be informative during the treatment procedure of cancer without needing to disturb the physician’s quantifiable workflow.

Clinical Pathways helps to remove probable presumptions. Clinical Pathways provides the latest cancer information, latest treatment procedures, and provides treatments that are complementary into Allscripts Sunrise EHR. These accessible possibilities enables oncologists the capability to make a list of protocols. Some of the benefits include custom procedures particular to the patient, various evaluations among treatment choices, access to latest guidelines, and subsidiary quantifiable information.

The blog, for Cancer Treatment Centers of America, Allscripts, and NantHealth created a developing plan in 2016 to support patients and benefactors. The developing plan helps these individuals gain advantages from quantifiable abilities when using a combined solution. The eviti resolution plays an essential part in getting the Clinical Pathway’s platform organized. Physicians are able to view present substantiation treatment procedures for all forms of cancer.

Cancer Treatment Centers of America’s headquarter is located in Florida. Cancer Treatment Centers of America is a system of five hospitals that assists patients dealing with cancer throughout the United States. Cancer Treatment Centers of America use a conventional method when trying to treat cancer. This network of hospitals also offers integrative treatments while treating cancer.

As stated on Wikipedia, Cancer Treatment Centers of America was established by Richard J Stephenson. The first Cancer Treatment Centers of America opened in the year 1988. Then four hospitals in association with this network opened between 2005 and 2012. Cancer Treatment Centers of America has consistently maintained strong patient satisfaction.

In conclusion, Cancer Treatment Centers of America lend a helping hand with cancer treatment.

For more information follow CTCA on Twitter.